在外周和中枢神经系统疾病中使用HDAC6抑制剂的治疗指示
Jonathan van Eyll1, Robert Prior2, Sylvain Celanire1
1Augustine Therapeutics, Research and Development, Leuven, Belgium.
Expert opinion on therapeutic targets
|September 21, 2024
概括
选择性抑制HDAC6 (基因组脱乙酶6) 显示出治疗外周和中枢神经系统疾病的前景. 新的化合物和方法正在开发中,以解决这些神经退行性疾病的安全问题.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 希斯脱乙酶6 (HDAC6) 在与神经系统疾病相关的细胞机制中发挥多因素作用.
- 周围神经系统 (PNS) 和中枢神经系统 (CNS) 疾病中常见的病理特征是由HDAC6活动调节的.
研究的目的:
- 审查HDAC6在PNS和中枢神经系统疾病中的作用.
- 分析HDAC6抑制和基因调制的治疗潜力.
- 讨论HDAC6抑制剂开发的进展和挑战.
主要方法:
- 对HDAC6抑制剂的临床前和临床研究的文献综述.
- 基因淘汰/淘汰研究的分析.
- 对HDAC6 PET标记剂的发展情况的回顾.
主要成果:
- 广泛的临床前证据支持神经退行性和衰老相关疾病的HDAC6抑制.
- 选择性HDAC6抑制剂在PNS和中枢神经系统的指示中都显示出有效性.
- 进步包括新的化合物类,如HDAC6降解剂和基于醇的抑制剂.
结论:
- 药理上抑制HDAC6是一种有前途的治疗策略,用于PNS和中枢神经系统疾病.
- 由于长期使用的安全问题,需要开发新的HDAC6向模式.
- 对选择性HDAC6抑制剂和PET追踪剂的进一步研究对于临床转化至关重要.
相关概念视频
Parkinson's Disease: Treatment
235
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
235
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
635
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
635
Drug Delivery: Parenteral Route
442
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
442
Antipsychotic Drugs: Therapeutic Uses and Side Effects
129
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
129


